Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures
Rhea-AI Summary
Milestone Scientific (NYSE American: MLSS) reported growing clinical adoption and physician acceptance of its CompuFlo Epidural System, supported by a new University of Texas Medical Branch study in Operative Neurosurgery.
The study found CompuFlo-guided spinal cord stimulator implantation was associated with a 91% reduction in odds of composite complications versus traditional loss-of-resistance techniques.
AI-generated analysis. Not financial advice.
Positive
- UTMB study shows CompuFlo guidance with 91% lower odds of composite complications in SCS procedures
- Peer-reviewed Operative Neurosurgery publication strengthens clinical evidence for CompuFlo technology
- Expanding use across multiple procedures, including ESIs, obstetric, thoracic, cervical, and surgical epidurals
- CompuFlo evaluated or used at more than 40 universities and major medical centers globally
- Real-time pressure sensing and audible feedback aim to enhance epidural accuracy and physician confidence
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed moves, with names like HBIO up 4.36% and RVP down 1.85%. Momentum data also show one peer up and one down, indicating today’s setup looks more stock-specific than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 2026 earnings | Negative | -4.3% | Soft revenue with improved losses and persistent going-concern language. |
| May 07 | Earnings call setup | Neutral | -2.6% | Scheduled Q1 2026 results and business update conference call. |
| May 07 | CompuFlo adoption update | Positive | +16.3% | Expansion of CompuFlo medical business and advisor program rollout. |
| Apr 21 | Private placement | Negative | +8.7% | $2.15M equity/warrant financing and potential additional dilution. |
| Mar 31 | FY 2025 earnings | Positive | +3.7% | Revenue growth, improved operating loss, and CompuFlo growth outlook. |
Recent news reactions mostly aligned with the nature of the announcements, with one notable divergence on a private placement that saw a positive price response.
Over the past few months, Milestone Scientific has combined financial updates with strategic progress. Earnings on Mar 31, 2026 and May 14, 2026 highlighted modest revenue, improving losses, and ongoing going-concern risk. A $2.15M private placement on Apr 21, 2026 strengthened liquidity, while the May 7, 2026 CompuFlo® business update coincided with a strong 16.26% gain, underscoring investor interest in medical adoption. Today’s article continues that adoption narrative around CompuFlo-guided epidural access.
Market Pulse Summary
The stock is up +5.3% following this news. A strong positive reaction aligns with prior enthusiasm around CompuFlo milestones, such as the 16.26% gain on the May 7 adoption update. The newly cited 91% reduction in complication odds strengthens the clinical case and could reinforce confidence in the medical growth story. However, investors would still need to weigh this against the company’s history of losses and capital raises when considering durability of any sharp move.
Key Terms
epidural medical
cerebrospinal fluid (csf) medical
neuromodulation medical
AI-generated analysis. Not financial advice.
ROSELAND, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments utilizing Dynamic Pressure Sensing™ (DPS) technology, today highlighted the continued growth in clinical adoption and physician acceptance of its CompuFlo® Epidural System following the publication of new peer-reviewed research from the University of Texas Medical Branch (UTMB).
The newly published study in Operative Neurosurgery demonstrated that CompuFlo-guided epidural access during spinal cord stimulator (SCS) implantation procedures was associated with significantly lower complication rates compared with conventional loss-of-resistance techniques.
The publication further demonstrates the expanding clinical acceptance of CompuFlo technology across a broad and growing range of procedures requiring accurate epidural space identification, including:
- Epidural Steroid Injections (ESIs)
- Spinal Cord Stimulator (SCS) implantation
- Chronic pain management procedures
- Obstetric epidurals
- Thoracic and cervical epidurals
- Neuromodulation therapies
- Surgical epidural anesthesia
CompuFlo provides physicians with continuous real-time pressure sensing and audible feedback during needle advancement, enabling objective identification of the epidural space and helping improve procedural precision, safety, and physician confidence.
In the UTMB study, CompuFlo guidance was associated with a
“This recent publication further highlights the value of this technology in chronic pain and neuromodulation procedures. As spinal procedures such as spinal cord stimulation and cervical or thoracic epidural access become increasingly sophisticated, real-time objective feedback during epidural access may help improve procedural precision, physician confidence, and overall procedural safety,” said Dr. Dawood Sayed, Professor of Anesthesiology and Pain Medicine at The University of Kansas Medical Center, Vice Chairman of the Board of The American Society of Pain and Neuroscience, and a member of Milestone Scientific’s Board of Directors.
“We are seeing increasing adoption of CompuFlo among physicians performing ESIs, spinal cord stimulation procedures, obstetric epidurals, and other neuraxial interventions,” said Eric Hines, CEO of Milestone Scientific. “CompuFlo technology has been evaluated or utilized across more than 40 universities, academic medical centers, and teaching hospitals worldwide, as clinicians increasingly recognize the value of objective, real-time pressure sensing to support procedural accuracy, patient safety, and confidence during epidural access.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
HAYDEN IR:
James Carbonara
(646)-755-7412
james@haydenir.com
Brett Maas
(646) 536-7331
brett@haydenir.com
